The aim of this single-centre prospective study was to assess the impact of preoperative mitral valve regurgitation (MR) on outcomes of patients undergoing transcatheter aortic valve implantation (TAVI).
INTRODUCTION
Severe calcific degenerative aortic valve stenosis (AS) is frequently associated with mitral valve regurgitation (MR). MR in AS develops mainly as a consequence of the aortic valve disease. In fact, AS causes pressure overload and concentric hypertrophy and, when this pathophysiologic condition is longstanding, progression towards left ventricular dilatation occurs and consequently MR develops. Furthermore, senile calcific aortic degeneration is often accompanied by some degree of mitral degeneration as well, and the coexistence of coronary artery disease, especially if a previous myocardial infarction occurred, can impact on the onset of MR. Aortic valve replacement is the treatment of choice in patients with severe symptomatic AS. It can be performed with low mortality rates and good long-term outcomes. However, in patients who are inoperable or at too-high risk for conventional surgery, transcatheter aortic valve implantation (TAVI) has shown satisfactory early and mid-term outcomes [1] [2] [3] . In the case of concomitant severe AS and severe mitral regurgitation, current guidelines recommend double-valve replacement while there is less agreement when MR is moderate or mild [4] . Indications for mitroaortic valve replacement should be carefully evaluated, since this procedure is associated with higher morbidity and mortality than simple aortic valve surgery [5, 6] . Even if there are some isolated report of TAVI with concomitant percutaneous treatment of MR [7, 8] , transcatheter mitroaortic procedures are not routinely performed since they are technically demanding and not standardized. Results of isolated TAVI in patients with concomitant AS and MR are unknown. Aims of this prospective single-centre study were to assess the impact of preoperative MR on the outcomes of patients undergoing TAVI and to evaluate MR changes after TAVI. [10] . In particular, device procedural success was defined as: (i) successful access, delivery and deployment of the device and successful retrieval of the delivery system; (ii) correct position of the device in the proper anatomical location; (iii) intended performance of the prosthetic heart valve (aortic valve area >1.2 cm 2 and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s, without moderate or severe prosthetic valve regurgitation); (vi) only one valve implanted in the proper anatomical location.
MATERIALS AND METHODS

Statistical analysis
Continuous data are expressed by the mean ± 1 SD. Categorical data are summarized by reporting the percentages. Categorical values were compared by the χ 2 -test or Fisher's exact test as appropriate, and continuous variables were compared by the Mann-Whitney test. Cumulative survival was estimated using the Kaplan and Meier method. Survival rates were compared by using the log-rank test. Univariate analysis was used to determine predictive factors for hospital mortality. A P-value of <0.05 was considered statistically significant. Statistical analysis was performed using SPSS software (Release 13.0 for Windows, Chicago, IL, USA).
RESULTS
Preoperative clinical characteristics of the overall population and of the two groups are summarized in Table 1 . Patients in the NoMR group were more likely to have lower logistic EuroSCORE (19.6 vs. 26.9%, P < 0.001) and less atrial fibrillation (16.5 vs. 34.9%, P = 0.004). Preoperative echocardiographic and haemodynamic parameters are shown in Table 2 . MR patients had larger left atrium, higher systolic and diastolic left ventricular volumes and worse ejection fraction if compared with NoMR patients. Furthermore, patients belonging to the MR group had higher pulmonary and wedge pressures and lower cardiac output values. The analysis of TAVI procedures did not show significant differences in terms of anaesthesia, transapical or transfemoral TAVI approach, implanted device, procedural success and post-operative aortic regurgitation (Table 3 ). In particular, overall procedural success was 95.4%, and in NoMR and MR groups, that was 96.5 and 93%, respectively (P = 0.38). Overall allcause hospital mortality was 4.5% (eight patients). In particular, all-cause hospital mortality in NoMR and MR groups was 3% (four patients) and 9.3% (four patients), respectively (P = 0.10).
Overall late mortality was 16.7% (28 patients). In particular, late death occurred in 20 patients (15.5%) in the NoMR group and in eight patients (20.5%) in the MR group (P = 0.46). Cardiovascular late mortality was 7.7% (13 patients) in the overall population and 7% (nine patients) and 10.3% (four patients) in MR and NoMR groups, respectively (P = 0.50). Stroke occurred in four patients (2.2%), three in the NoMR group and one patient in the MR group (P = 1.00). The Kaplan-Meier survival 20 months after TAVI was 78 ± 8% in the MR group and 75 ± 6% in the NoMR group (P = 0.2; Fig. 1 ). At echocardiographic follow-up, we observed in the MR group, but not in the NoMR group, a significant improvement of left ventricular ejection fraction, a significant reduction in left ventricular volumes and a significant reduction in right ventricular systolic pressure (Table 4 ). Out of the 43 patients of the MR group, at follow-up, 12 patients (27.9%) experienced a significant reduction in MR degree that resulted <2+, and among these, in 8 patients, a significant MR degree reduction was already visible 48 h after TAVI. On the other hand, out of the 133 patients of the NoMR group, we observed in 12 patients (9%) a MR degree worsening that increased from 1+ to 2+. Changes of left ventricular end-diastolic and end-systolic volume indices, ejection fraction and right ventricular systolic pressure between pre-and post-operative measurements as well as their trend over time during follow-up in the overall population and in the two groups are shown in Fig. 2 .
The following variables were found to be predictive factors for hospital mortality at the univariate analysis: procedural success, logistic EuroSCORE, left ventricular ejection fraction, right ventricular systolic pressure, pulmonary artery systolic pressure and wedge pressure. At follow-up, we observed a significant reduction in the New York Hear Association (NYHA) functional class in both groups (Fig. 3) .
DISCUSSION
Mitral regurgitation is often associated with AS. Double-valve replacement is indicated in the case of concomitant severe MR and AS but the mortality rate associated with this procedure is significantly higher than isolated aortic valve replacement [5, 6] . There is still debate in the literature as to whether operate or not the mitral valve in patients with moderate MR and AS. Barreiro et al. [11] in a retrospective review of 408 consecutive patients who underwent isolated aortic valve replacement found that, in patients with moderate MR, only those with a functional aetiology experienced an improvement of MR, whereas those with MR due to other aetiologies (myxomatous, calcific, ischaemic) remain unchanged or worsened. Furthermore, they found that moderate MR was an independent risk factor impacting the long-term survival in elderly patients undergoing aortic valve replacement. Harling et al. [12] in their systematic literature review and meta-analysis of 3053 patients undergoing aortic valve replacement for AS with co-existing MR found that moderatesevere MR adversely affects both early and late mortality following aortic valve replacement and conclude that concomitant mitral intervention should be considered in the presence of moderate MR, independent of the aetiology. Conversely, Wan et al. [13] from the Mayo clinic found that, in 686 patients with at least moderate MR undergoing aortic valve replacement, moderate functional MR improved in most patients after aortic valve replacement and that residual MR did not affect survival independently of left ventricular function. In the case of patients with severe AS and at least moderate MR scheduled for TAVI, the questions are: will MR improve after TAVI? Will the patient benefit from TAVI even if moderate-severe MR remains unchanged? Does preoperative MR affect post-TAVI survival? From the answers to these questions derives the decision whether to perform TAVI or give only medical treatment to these extremely fragile patients. Even if there is some promising report of concomitant percutaneous treatment of AS with TAVI and MR with the Mitraclip device (Abbott Laboratories, Abbot Park, IL, USA) [7, 8] , the combined transcatheter technique experience is still very limited and safety and efficacy are yet to be proved. Consequently, patients scheduled for TAVI with an associated moderate-severe MR are only treated with TAVI and MR is left untreated. We sought to evaluate if MR had an impact on TAVI patients' outcomes in order to better understand the optimal therapeutic strategy for these challenging patients. TAVI is indicated in patients with severe symptomatic AS who are inoperable or have a high risk for conventional surgery. In these patients, the presence of moderate-severe MR represents a therapeutic challenge and there are few data about patient outcomes. We analysed all TAVI patients performed at our institution. We included transapical, transfemoral and trans-subclavian approaches and we divided patients into two groups according to the presence and the degree of MR. The incidence of moderate-severe MR (≥2+) in our TAVI population was 24% and is consistent with that found in the population undergoing conventional aortic valve replacement [11, 14] . These patients had a significantly higher logistic EuroSCORE than NoMR patients and worse echocardiographic and haemodynamic parameters like left ventricular ejection fraction, pulmonary pressure and ventricular volumes. We observed a trend towards a higher hospital mortality in the MR group but 20-month Kaplan-Meier survival was similar between groups. Furthermore, MR did not appear to be a significant risk factor for hospital mortality. The similar 20-month survival between groups, despite the trend towards a higher initial hospital mortality in the MR group, can be explained by the left ventricular remodeling that occurs in an MR patient after TAVI. In fact, during the follow-up, we observed a significant improvement of left ventricular ejection fraction and a significant reduction in both left ventricular systolic and diastolic volumes in MR patients, as shown in Table 4 . Even if only 28% of patients with MR ≥ 2+ showed a significant reduction in MR degree, the correction of the aortic valve pathology seems to be sufficient in order to reduce left ventricular dimensions and improve patient outcomes. Furthermore, during the follow-up, we observed a significant improvement of NYHA functional class in the MR group, similar to NoMR patients. These are important findings especially if one considers that this is an elderly population with a mean age of 80 years and consequently the incidence of 'pure' functional MR is low since the great majority of these patients have some degree of mitral calcification involving both annulus and leaflets. Certainly, there are many factors that should be taken into consideration before TAVI in patients with mitroaortic disease: anatomy, pathophysiology and degree of MR, left ventricular dimensions, pulmonary pressure and tricuspid insufficiency. The next step in this field should be to identify predictors of MR improvement after TAVI in order to carefully select patients who will most benefit from the procedure and to exclude those with poor post-operative prognosis in terms of MR improvement, survival and relief from symptoms. In this context, Durst et al. [15] found that mitral annular calcification with restriction was the only variable associated with a reduction in MR improvement after TAVI. The main limitation of this study was the lack of data from patients who were excluded from TAVI for the presence of a severe MR since it would have been interesting to analyse and compare patient outcomes. However, we usually do not perform TAVI in patients with severe (4+) degenerative MR, since there are very few chances to reduce MR and to improve clinical conditions in these patients. Furthermore, the follow-up is still short but further evaluation is warranted in order to assess survival throughout a longer period of time.
In conclusion, our data show that inoperable or high-risk patients with severe AS and concomitant moderate-severe MR undergoing TAVI have a trend towards higher hospital mortality. However, MR was not identified as a risk factor for mortality. At the follow-up, a reduction in MR, an improvement of left ventricular echocardiographic parameters and a significant improvement of NYHA class were observed. Therefore, these data justify a 'TAVI-only' procedure even in the presence of moderatesevere MR in high-risk or inoperable patients. In view of extending TAVI indications to less compromised and younger patients, future clinical decision-making about isolated TAVI in patients with concomitant significant MR should be based on the longterm observation of survival of the two groups.
Dr Walther: I have one other suggestion, to look at a large database, SOURCE, for example, and see whether it turns out to be a significant impact.
Dr Wendler: You don't get it from SOURCE because the SOURCE echo data are not core-lab adjudicated. I think you get it from larger centres. I mean, I will go back and do it on our 350 patients done at King's; Leipzig definitely can do it in their patient group. I think it is something which individual centres should do, because then you have consistency in how you analyse the echo.
